For someone who has already tried several antidepressants, hearing about another medication can understandably feel less exciting than it sounds. Another prescription may seem like another round of waiting, another dose adjustment, and another attempt to influence the same symptoms through a slightly different drug. Spravato, however, does not fit neatly into that familiar pattern. It contains esketamine, is administered as a nasal spray under direct medical supervision, and works through a different neurochemical system than many conventional antidepressants. In the United States, Spravato is currently approved for treatment-resistant depression in adults either as a standalone treatment or together with an oral antidepressant. It is also approved, together with an oral antidepressant, for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior. 

That distinction matters because Spravato is not simply a new brand name attached to the traditional antidepressant model. Its mechanism, treatment setting, monitoring requirements, clinical role, and patient experience are different. For people whose depression has remained difficult to treat, those differences can change the conversation from simply choosing another antidepressant to considering whether another treatment strategy is appropriate.

Traditional Antidepressants Usually Follow a Familiar Model

Most people who begin medication for depression enter a treatment process built around conventional antidepressants. Selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, and several other medication classes remain important tools in psychiatric care. These medications can be highly effective, and many patients achieve substantial improvement through standard treatment.

The difficulty is that response is not predictable. A medication that works well for one patient may produce little change for another. Some people experience partial improvement but continue struggling with low motivation, hopelessness, concentration difficulties, sleep disturbance, emotional withdrawal, or impaired daily functioning. Others discontinue medications because side effects become difficult to tolerate.

When the first medication does not provide enough benefit, clinicians may adjust the dose, switch medications, combine treatments, or add psychotherapy and other interventions. This process is reasonable and evidence based, but repeated unsuccessful trials can eventually suggest that the treatment plan needs more than another variation of the same approach.

Treatment-Resistant Depression Changes the Question

Treatment-resistant depression generally describes major depression that has not responded adequately to appropriate antidepressant treatment. The current FDA prescribing information for Spravato describes clinical studies involving adults who had failed to respond adequately to at least two antidepressants of adequate dose and duration during the current depressive episode. (FDA Access Data)

Reaching this stage does not mean conventional antidepressants are ineffective in general, nor does it mean a patient has exhausted every possible option. It means previous treatment history has become clinically important enough to justify looking more broadly at what might come next.

A careful psychiatrist will usually examine more than the number of medications on a patient's history. Treatment duration, dosage, adherence, side effects, psychiatric diagnoses, physical health, sleep, substance use, trauma, current medications, and previous therapeutic responses may all influence the next decision.

Spravato Works Through a Different Neurochemical System

One of the biggest reasons Spravato should not be viewed as simply another conventional antidepressant is its pharmacology. Spravato contains esketamine and is classified as a noncompetitive N-methyl-D-aspartate, or NMDA, receptor antagonist. NMDA receptors are involved in the brain's glutamate signaling system. 

Many traditional antidepressants are discussed primarily in relation to monoamine neurotransmitters such as serotonin and norepinephrine. Esketamine shifted attention toward glutamate, the brain's major excitatory neurotransmitter, and toward broader questions involving neural signaling, synaptic communication, and plasticity.

Researchers continue to investigate precisely how ketamine-related treatments produce antidepressant effects. It would therefore be misleading to claim that scientists have reduced Spravato's effect to one simple molecular explanation. Research into ketamine and related compounds has shown that the biological story is more complicated than simply blocking one receptor. 

Why a Different Mechanism Matters

The significance of this different mechanism becomes easier to understand when considering someone who has already spent years trying medications that operate through more familiar antidepressant pathways. If several adequately managed treatments have failed to provide enough relief, simply choosing another medication with a broadly similar therapeutic strategy may not always be the most compelling next step.

Spravato gives clinicians another pharmacologic route to consider. This does not mean its mechanism automatically makes it superior. It means it provides an option based on a substantially different treatment model, which can be particularly relevant in treatment-resistant depression.

Spravato Is Also Different in How It Is Given

A traditional antidepressant usually becomes part of a person's daily routine. The prescription is filled, the medication is taken at home, and follow-up appointments occur periodically to monitor symptoms and side effects.

Spravato does not work that way.

The medication is administered as a nasal spray during a supervised treatment session. According to current FDA prescribing information, Spravato must be given under the direct supervision of a healthcare provider, and the treatment session includes both nasal administration and a period of post-administration observation.

This structure creates a very different patient experience. Treatment requires scheduled appointments, time at the healthcare facility, monitoring, and transportation planning. Spravato therefore asks more of both the patient and the treatment provider than swallowing a tablet at home.

Monitoring Is Built Into the Treatment

The supervised setting is not simply an administrative requirement. Esketamine can temporarily produce significant effects that need to be monitored.

Patients are monitored for changes in respiratory status, and blood pressure is assessed before and after treatment. Spravato can also cause sedation, dizziness, nausea, dissociation, temporary perceptual changes, and increases in blood pressure. Current prescribing information requires post-treatment monitoring and states that patients need transportation home following treatment. 

These requirements highlight an important difference between Spravato and standard antidepressant prescribing. The treatment experience itself is medically supervised because the medication can cause short-term effects that occur around the time it is administered.

The Experience Can Feel Different, But the Experience Is Not the Goal

Some patients experience dissociation during Spravato treatment. This can involve changes in perception, altered awareness of time or surroundings, or a feeling of separation from one's body or usual sense of self. Others may mainly experience dizziness, sedation, nausea, or a sense that things feel temporarily unusual.

Because these effects can be noticeable, people sometimes assume that a stronger subjective experience means a stronger antidepressant response. That conclusion should not be made automatically.

The purpose of treatment is not to create an unusual experience during the appointment. The meaningful outcome is whether depression improves outside the treatment setting.

Clinicians Look for Changes in Everyday Life

A psychiatrist may monitor changes in mood, motivation, hopelessness, concentration, sleep, social functioning, work performance, self-care, and the ability to participate in ordinary activities. These measures provide a better picture of treatment response than how intense or memorable a single treatment session felt.

For someone with severe depression, improvement can initially appear surprisingly ordinary. Answering messages, preparing meals, returning to work, getting out of bed more consistently, reconnecting with family, or becoming more engaged in therapy can all signal meaningful progress.

Depression often removes normal functioning gradually. Treatment success can therefore involve getting pieces of normal life back rather than suddenly feeling transformed.

Spravato Follows a Structured Treatment Course

Spravato is also different from the idea of taking one dose and immediately deciding whether the medication works. For treatment-resistant depression, the FDA-approved treatment framework includes an induction phase followed by less frequent treatment during later phases when continued therapy is appropriate. The prescribing information specifically recommends evaluating therapeutic benefit after the induction phase when deciding whether treatment should continue. 

This means treatment is assessed over time. Clinicians consider both efficacy and tolerability and may adjust the treatment plan according to how the patient responds.

One Session Does Not Tell the Whole Story

The first treatment can provide useful information about tolerability, but it does not necessarily establish the long-term outcome. Some patients may notice improvement relatively early, while others may require additional treatment before the clinical picture becomes clearer.

Similarly, an early response does not automatically tell clinicians how durable that response will be. Long-term depression management still requires follow-up, symptom monitoring, and decisions about whether the benefits continue to outweigh the burdens and risks of treatment.

This is another reason Spravato should be understood as a treatment program rather than simply a medication product.

Spravato Is Not the Same as Ketamine Infusion Therapy

Because Spravato contains esketamine, conversations about Spravato and ketamine are often blended together. They are related, but they are not interchangeable treatments.

Ketamine is a mixture containing two molecular forms, while esketamine is one specific form. Spravato is an intranasal esketamine product with specific FDA-approved psychiatric indications. Intravenous ketamine, by contrast, is FDA-approved as an anesthetic but is commonly used off-label in some clinical settings for depression.

The distinction matters because administration, regulatory status, dosing protocols, treatment settings, monitoring requirements, and insurance coverage can differ substantially.

Similar Origins Do Not Mean Identical Treatment

Patients researching depression care may encounter terms such as ketamine therapy, ketamine infusion, esketamine, and Spravato used as though they describe one treatment. That can create unnecessary confusion.

A good clinical discussion should clearly identify what medication is being offered, how it is administered, what evidence supports that specific treatment, what regulatory framework applies, and how the patient will be monitored.

For someone evaluating treatment options, understanding these differences is much more useful than simply hearing that both treatments are related to ketamine.

Spravato Is Not Automatically the Next Step After One Medication Fails

Another misconception is that Spravato is designed for anyone who did not respond to their first antidepressant. Its role in treatment-resistant depression is more specific.

Clinicians need to understand whether previous treatment trials were adequate and whether the diagnosis and overall treatment strategy still make sense. Someone who has received only limited treatment may still have several conventional options worth exploring before Spravato becomes relevant.

Patient Selection Requires More Than a Diagnosis

A person's medical and psychiatric history matters because Spravato has important contraindications, warnings, and precautions. Blood pressure and cardiovascular considerations can influence treatment decisions. Clinicians also need to evaluate risks related to sedation, dissociation, respiratory depression, abuse and misuse, and other individual factors. Spravato is available through a restricted REMS program because of several of these risks. 

This does not make Spravato inherently inappropriate or unusually alarming. It means it is a serious medical treatment that needs to be prescribed within the correct clinical framework.

The strongest treatment programs therefore begin with assessment rather than promotion. The important question is not whether someone wants Spravato. It is whether their clinical history suggests that Spravato is an appropriate option.

Spravato Can Now Be Used Without an Oral Antidepressant for TRD

One important development changed how Spravato can be used for treatment-resistant depression. In January 2025, the FDA-approved labeling was expanded so that Spravato can be used either as monotherapy or together with an oral antidepressant for adults with treatment-resistant depression. (FDA Access Data)

This is important because older articles and patient information may still describe Spravato as something that must always be taken alongside a newly initiated oral antidepressant. That was previously the treatment framework, but it is no longer the complete current picture for treatment-resistant depression in the United States.

For depressive symptoms in adults with major depressive disorder accompanied by acute suicidal ideation or behavior, however, current FDA labeling still specifies Spravato in conjunction with an oral antidepressant. The label also states that effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated. 

Different Does Not Mean Effortless

Spravato's differences can make it clinically valuable, but those same differences create practical demands.

Patients need to attend treatment sessions rather than simply taking medication at home. They need time for administration and monitoring. Transportation must be planned. Temporary side effects may disrupt the rest of the treatment day, and regular appointments can affect work, childcare, travel, and other responsibilities.

Cost and insurance coverage may create additional considerations. Availability also depends on access to appropriately certified treatment settings.

The Practical Burden Is Part of the Decision

A treatment can be clinically promising and still be difficult to integrate into a person's life. That practical reality should be discussed before therapy begins.

For one patient, regular supervised treatment may be manageable. For another, transportation, scheduling, medical conditions, or financial considerations may make a different treatment strategy more realistic.

Good psychiatric care considers these factors rather than evaluating treatment exclusively through clinical trial results. The best treatment is not merely the one with an interesting mechanism. It must also be medically appropriate and realistically sustainable for the person receiving it.

Spravato Does Not Replace the Rest of Depression Care

Because Spravato represents a newer treatment approach, there can be a temptation to view it as the main solution once conventional medications have failed. Depression care is usually more complicated than that.

Psychotherapy, management of coexisting psychiatric conditions, physical health, sleep, social support, substance-use treatment when relevant, and ongoing psychiatric follow-up may all remain important. Some patients may also continue other psychiatric medications depending on their treatment plan.

Symptom Improvement Can Create Room for Recovery

One potential value of reducing severe depressive symptoms is that patients may become better able to participate in other parts of recovery.

A person who previously struggled to concentrate during therapy may become more engaged. Someone who lacked the energy to maintain basic routines may begin rebuilding them. Relationships that became difficult to maintain during severe depression may gradually become easier to reconnect with.

The larger goal is therefore not simply successful administration of Spravato. It is improved functioning and a more sustainable recovery process.

Why Spravato Represents More Than Another Prescription

The importance of Spravato lies partly in what it represents about the evolution of depression treatment. Traditional antidepressants remain essential and effective for many people, but they do not work adequately for everyone. Research involving ketamine and esketamine helped demonstrate that clinically meaningful antidepressant effects can be pursued through biological systems outside the mechanisms emphasized by many traditional medications. NIMH research into ketamine helped broaden scientific interest in glutamate-related mechanisms and rapid-acting antidepressant approaches.

Spravato brought part of that scientific shift into a regulated clinical treatment for specific depressive conditions. That is why describing it as simply another antidepressant misses the larger picture.

It uses a different mechanism, requires a different treatment environment, creates a different patient experience, and has a different role in the treatment pathway.

Conclusion

Spravato is not just another antidepressant because nearly every part of the treatment model is different from what many patients have experienced with traditional medication. It contains esketamine, acts through NMDA and glutamate-related pathways, is administered as a supervised nasal treatment, requires structured monitoring, and is primarily positioned for clinical situations in which depression has proved difficult to treat.

Those differences do not make Spravato automatically better than conventional antidepressants, and they do not mean every person with persistent depression should receive it. Traditional medications continue to help many people, and treatment decisions must always reflect the individual's diagnosis, history, health, previous response, risks, preferences, and practical circumstances.

What Spravato offers is another therapeutic direction. For some adults with treatment-resistant depression, that direction may become relevant precisely because the familiar antidepressant pathway has not produced enough improvement. The value of Spravato is therefore not that it replaces the traditional playbook. It is that modern depression care no longer has to rely on only one playbook when the first one is not enough.